Literature DB >> 21479447

Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis.

Mitsuteru Kitade1, Hitoshi Yoshiji, Hideyuki Kojima, Yasuhide Ikenaka, Ryuichi Noguchi, Kosuke Kaji, Junichi Yoshii, Koji Yanase, Tadashi Namisaki, Masaharu Yamazaki, Tatsuhiro Tsujimoto, Kei Moriya, Hideto Kawaratani, Takemi Akahane, Hiroshi Fukui.   

Abstract

Reactive oxygen species (ROS) is known to play an important role in the pathogenesis of non-alcoholic steatohepatitis (NASH); however, as we previously reported, angiogenesis also plays a pivotal role in NASH progression - the development of liver fibrosis and hepatocellular carcinoma - in rats. The aim of the current study was to elucidate the role of angiogenesis in the development of fibrosis in NASH. Twenty-six patients with NASH and 11 with simple fatty liver (FL) disease were enrolled in the study and underwent clinicopathological examination. Immunohistochemical analysis of 4-hydroxy-2-noneal (4-HNE) and CD34 was employed for the detection of ROS and angiogenesis in the liver tissues, respectively. Both the NASH and FL samples displayed a marked staining of 4-HNE as compared to the healthy liver. Similar levels of 4-HNE were observed in NASH regardless of the grade of liver fibrosis. In sharp contrast, hepatic neovascularization developed significantly in NASH alone, whereas almost no neovascularization was observed in FL or the healthy liver. The degree of angiogenesis was almost parallel with the development of liver fibrosis. In conclusion, simple FL and NASH cases were both affected by ROS. However, only NASH was associated with marked neovascularization, proportional to the increase in the grade of liver fibrosis development. These results indicate that hepatic neovascularization may play an important role in the onset and progression of NASH.

Entities:  

Year:  2008        PMID: 21479447

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  14 in total

1.  Hepatic fibrosis developing in morbid obesity independent of steatohepatitis: new mechanism or the Rube Goldberg machine?

Authors:  Eric R Kallwitz
Journal:  Hepatol Int       Date:  2012-03-11       Impact factor: 6.047

2.  Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans.

Authors:  K N Aronis; K N Diakopoulos; C G Fiorenza; J P Chamberland; C S Mantzoros
Journal:  Diabetologia       Date:  2011-06-10       Impact factor: 10.122

3.  Tie-ing Up Angiogenesis to Treat Nonalcoholic Steatohepatitis.

Authors:  Nicholas O Davidson
Journal:  Hepatology       Date:  2019-02-08       Impact factor: 17.425

4.  Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis.

Authors:  Mitsuteru Kitade; Hitoshi Yoshiji; Ryuichi Noguchi; Yasuhide Ikenaka; Kosuke Kaji; Yusaku Shirai; Masaharu Yamazaki; Masahito Uemura; Junichi Yamao; Masao Fujimoto; Akira Mitoro; Masahisa Toyohara; Masayoshi Sawai; Motoyuki Yoshida; Chie Morioka; Tatsuhiro Tsujimoto; Hideto Kawaratani; Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2009-11-07       Impact factor: 5.742

5.  Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells.

Authors:  Davide Povero; Akiko Eguchi; Ingrid R Niesman; Nektaria Andronikou; Xavier de Mollerat du Jeu; Anny Mulya; Michael Berk; Milos Lazic; Samjana Thapaliya; Maurizio Parola; Hemal H Patel; Ariel E Feldstein
Journal:  Sci Signal       Date:  2013-10-08       Impact factor: 8.192

6.  Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.

Authors:  Lindsay T Fourman; Takara L Stanley; James M Billingsley; Shannan J Ho Sui; Meghan N Feldpausch; Autumn Boutin; Isabel Zheng; Colin M McClure; Kathleen E Corey; Martin Torriani; David E Kleiner; Colleen M Hadigan; Raymond T Chung; Steven K Grinspoon
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

7.  Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH).

Authors:  Savneet Kaur; Preety Rawal; Hamda Siddiqui; Sumati Rohilla; Shvetank Sharma; Dinesh M Tripathi; Sukriti Baweja; Mohsin Hassan; Sebastian Vlaic; Reinhard Guthke; Maria Thomas; Rania Dayoub; Chaggan Bihari; Shiv K Sarin; Thomas S Weiss
Journal:  Cells       Date:  2019-10-18       Impact factor: 6.600

8.  Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH.

Authors:  Ying Lu; Xiaolan Su; Manyu Zhao; Qianru Zhang; Chuang Liu; Qinhuai Lai; Sijia Wu; Aiping Fang; Jinliang Yang; Xiaoxin Chen; Yuqin Yao
Journal:  PeerJ       Date:  2019-12-20       Impact factor: 2.984

9.  The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease.

Authors:  Laia Bertran; Angela Pastor; Marta Portillo-Carrasquer; Jessica Binetti; Carmen Aguilar; Salomé Martínez; Margarita Vives; Fàtima Sabench; José Antonio Porras; David Riesco; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

Review 10.  The Role of Sinusoidal Endothelial Cells in the Axis of Inflammation and Cancer Within the Liver.

Authors:  Alex L Wilkinson; Maria Qurashi; Shishir Shetty
Journal:  Front Physiol       Date:  2020-08-28       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.